Zero hour nears in Europe

FDA's 'Egregious' Delays

Compared to the U.S., where follow-on biologics are creeping toward the market, Europe is racing forward. European consumers could be seeing FOBs - biosimilars in Eurospeak - on pharmacy shelves this year. Sandoz Inc. CEO Andreas Rummelt told BioCentury the company expects to receive EC approval for its Omnitrope human growth hormone in the next two weeks...